Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHC (polyphenol-rich fractions) is a combination of extracts derived from commonly consumed spices (Allium sativum L, Zingiber officinale R, Curcuma longa L) and herbs (Terminalia arjuna W & A, Cyperus rotundus L). It is being investigated for its anti-atherosclerotic activity, primarily by inhibiting lipid-laden macrophage foam cell formation and modulating various signaling pathways involved in atherogenesis. PHC has demonstrated the ability to attenuate the expression of CD36, p-FAK, and PPAR-γ, suppress NK-κB-DNA interaction, and reduce the expression of TNF-α, MMP9, and MMP2, while also enhancing macrophage migration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PHC.